Compare PSX & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSX | GSK |
|---|---|---|
| Founded | 1875 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4B | 93.3B |
| IPO Year | 2011 | 2013 |
| Metric | PSX | GSK |
|---|---|---|
| Price | $282.94 | $50.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 9 |
| Target Price | ★ $280.47 | $60.51 |
| AVG Volume (30 Days) | 2.1M | ★ 4.8M |
| Earning Date | 10-28-2026 | 10-28-2026 |
| Dividend Yield | 1.78% | ★ 3.49% |
| EPS Growth | ★ 116.23 | N/A |
| EPS | ★ 10.05 | N/A |
| Revenue | ★ $132,376,000,000.00 | N/A |
| Revenue This Year | $29.89 | $3.80 |
| Revenue Next Year | N/A | $4.72 |
| P/E Ratio | ★ $28.26 | $32.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $127.16 | $42.89 |
| 52 Week High | $299.39 | $61.70 |
| Indicator | PSX | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 57.86 | 59.57 |
| Support Level | $248.51 | $49.92 |
| Resistance Level | N/A | $51.65 |
| Average True Range (ATR) | 8.34 | 0.87 |
| MACD | -0.71 | 0.51 |
| Stochastic Oscillator | 50.79 | 87.52 |
Phillips 66 is an independent refiner that owns or holds interest in 10 refineries with a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, at the end of 2025. The midstream segment comprises extensive transportation and NGL processing assets. It includes 70,000 miles of crude oil, refined petroleum product, NGL and natural gas pipeline systems, and a comprehensive set of refined petroleum product, NGL and crude oil terminals, gathering and processing plants and fractionation facilities and various other storage and loading facilities. Its CPChem chemical joint venture operates facilities primarily in the United States and the Middle East and produces olefins and polyolefins.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.